JP2023507142A5 - - Google Patents
Info
- Publication number
- JP2023507142A5 JP2023507142A5 JP2022537047A JP2022537047A JP2023507142A5 JP 2023507142 A5 JP2023507142 A5 JP 2023507142A5 JP 2022537047 A JP2022537047 A JP 2022537047A JP 2022537047 A JP2022537047 A JP 2022537047A JP 2023507142 A5 JP2023507142 A5 JP 2023507142A5
- Authority
- JP
- Japan
- Prior art keywords
- tcr
- mhc
- antigen
- cells
- peptide complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025169565A JP2026010019A (ja) | 2019-12-16 | 2025-10-07 | 多重特異性ｔ細胞受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962948691P | 2019-12-16 | 2019-12-16 | |
| US62/948,691 | 2019-12-16 | ||
| PCT/US2020/065147 WO2021126872A1 (en) | 2019-12-16 | 2020-12-15 | Multi-specific t cell receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025169565A Division JP2026010019A (ja) | 2019-12-16 | 2025-10-07 | 多重特異性ｔ細胞受容体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023507142A JP2023507142A (ja) | 2023-02-21 |
| JP2023507142A5 true JP2023507142A5 (https=) | 2023-12-13 |
Family
ID=76476722
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022537047A Pending JP2023507142A (ja) | 2019-12-16 | 2020-12-15 | 多重特異性ｔ細胞受容体 |
| JP2025169565A Pending JP2026010019A (ja) | 2019-12-16 | 2025-10-07 | 多重特異性ｔ細胞受容体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025169565A Pending JP2026010019A (ja) | 2019-12-16 | 2025-10-07 | 多重特異性ｔ細胞受容体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230272036A1 (https=) |
| EP (1) | EP4076510A4 (https=) |
| JP (2) | JP2023507142A (https=) |
| KR (1) | KR20220116458A (https=) |
| CN (1) | CN114828877A (https=) |
| AU (1) | AU2020404933A1 (https=) |
| CA (1) | CA3161826A1 (https=) |
| WO (1) | WO2021126872A1 (https=) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ331688A (en) * | 1996-03-28 | 2000-02-28 | Univ Johns Hopkins | Soluble divalent and multivalent heterodimeric analogs of proteins |
| US10532099B2 (en) * | 2016-10-18 | 2020-01-14 | Oregon Health & Science University | Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules |
| US11384365B2 (en) * | 2018-03-19 | 2022-07-12 | Boehringer Ingelheim Vetmedica Gmbh | EHV with inactivated UL18 and/or UL8 |
-
2020
- 2020-12-15 WO PCT/US2020/065147 patent/WO2021126872A1/en not_active Ceased
- 2020-12-15 EP EP20903063.4A patent/EP4076510A4/en active Pending
- 2020-12-15 US US17/786,186 patent/US20230272036A1/en active Pending
- 2020-12-15 JP JP2022537047A patent/JP2023507142A/ja active Pending
- 2020-12-15 CA CA3161826A patent/CA3161826A1/en active Pending
- 2020-12-15 AU AU2020404933A patent/AU2020404933A1/en not_active Abandoned
- 2020-12-15 KR KR1020227021089A patent/KR20220116458A/ko active Pending
- 2020-12-15 CN CN202080087017.9A patent/CN114828877A/zh active Pending
-
2025
- 2025-10-07 JP JP2025169565A patent/JP2026010019A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Münz | Latency and lytic replication in Epstein–Barr virus-associated oncogenesis | |
| JP2018510650A5 (https=) | ||
| Boyle et al. | Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction | |
| Saha et al. | Epstein-Barr virus–associated B-cell lymphomas: pathogenesis and clinical outcomes | |
| EP3529363B1 (en) | Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules | |
| van Zyl et al. | Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in mice | |
| King et al. | A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance | |
| Kosinska et al. | Combination of DNA prime–adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model | |
| JP2021121185A (ja) | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 | |
| KR102857666B1 (ko) | 항-tcr-복합체 항체 또는 단편을 암호화하는 군 b 아데노바이러스 | |
| Ma et al. | Toward a functional cure for hepatitis B: the rationale and challenges for therapeutic targeting of the B cell immune response | |
| Ruiss et al. | A virus-like particle-based Epstein-Barr virus vaccine | |
| JP2019531745A5 (https=) | ||
| Flaño et al. | A mouse model for infectious mononucleosis | |
| Kamphorst et al. | CD4 T-cell immunotherapy for chronic viral infections and cancer | |
| JP2019502371A5 (https=) | ||
| CN112189018A (zh) | 结合疱疹病毒抗原的嵌合抗原受体和car-t细胞 | |
| Dai et al. | HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells | |
| Salnikov et al. | The viral etiology of EBV-associated gastric cancers contributes to their unique pathology, clinical outcomes, treatment responses and immune landscape | |
| Zhang et al. | GMP development and preclinical validation of CAR-T cells targeting a lytic EBV antigen for therapy of EBV-associated malignancies | |
| Fiedler et al. | Prime/boost immunization with DNA and adenoviral vectors protects from hepatitis D virus (HDV) infection after simultaneous infection with HDV and woodchuck hepatitis virus | |
| Yu et al. | A recombinant pseudotyped lentivirus expressing the envelope glycoprotein of hantaan virus induced protective immunity in mice | |
| Ynga-Durand et al. | Vaccine vectors harnessing the power of cytomegaloviruses | |
| JP2022512538A5 (https=) | ||
| Jiang et al. | Oncolytic cytomegaloviruses expressing EGFR-retargeted fusogenic glycoprotein complex and drug-controllable interleukin 12 |